Prolongation of skin xenograft survival with modified cultured fibroblasts

Plastic and Reconstructive Surgery

Volumn 111, Issue 1, 2003, Pages 275-282

  Işik, Selçuk ^a   Er, Ergin ^a   Soysal, Yasemin ^a   Imirzalioǧlu, Nejat ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPOSITE GRAFT; CONTROLLED STUDY; FIBROBLAST CULTURE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; IMPLANTATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN BIOPSY; STATISTICAL SIGNIFICANCE; XENOGRAFT;

EID: 0037215498     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006534-200301000-00046     Document Type: Article

References (44)

1. Murray, J. E. Organ transplantation (skin, kidney, heart) and the plastic surgeon. Plast. Reconstr. Surg. 47: 425, 1971.
2. Platt, J. L., Lin, S. S., and Shaikh, R. Future promises. In J. A. Fishman and D. H. Sachs (Eds.), Xenotransplantation: Scientific Frontiers and Public Policy. New York: New York Academy of Sciences, 1998. Pp. 5-19.
3. Lanzavecchia, A. Identifying strategies for immune intervention. Science 260: 937, 1993.
4. Nossal, G. J. Immunologic tolerance: Collaboration between antigen and lymphokines. Science 245: 147, 1989.
5. Webb, S., Morris, C., and Sprent, J. Extrathymic tolerance of mature T cells: Clonal elimination as consequence of immunity. Cell 63: 1249, 1990.
6. Kahan, B. D. Cyclosporine. N. Engl. J. Med. 321: 1725, 1989.
7. Starzl, T. E., Rao, A. S., Murase, P. N., Demetris, A. J., Thomson, A., and Fung, J. J. Chimerism and xenotransplantation: New concepts. Surg. Clin. North Am. 79: 191, 1999.
8. Achauer, B. M., Hewitt, C. W., Black, K. S., et al. Long-term skin allograft survival after short-term cyclosporin treatment in a patient with massive burns. Lancet 1: 14, 1986.
9. Mindikoǧlu, A. N., and Cetinkale, O. Prolonged allograft survival in a patient with extensive burns using cyclosporin. Burns 19: 70, 1993.
10. Sakabu, S. A., Hansbrough, J. F., Cooper, M. L., et al. Cyclosporine A for prolonging allograft survival in patients with massive burns. J. Burn Care Rehabil. 11: 410, 1990.
11. Frame, J. D., Sanders, R., Goodacre, T. E., et al. The fate of meshed allograft skin in burned patients using cyclosporin immunosuppression. Br. J. Plast. Surg. 42: 27, 1989.
12. Eldad, A., Benmeir, P., Weinberg, A., et al. Cyclosporin A treatment failed to extend skin allograft survival in two burned patients. Burns 20: 262, 1994.
13. Shihab, F. S. Cyclosporine nephropathy: Pathophysiology and clinical impact. Semin. Nephrol. 16: 536, 1996.
14. Lai, C. S., Miskell, P. H., Gonce, S. J., et al. Combined use of topical CsA and silver sulphadiazine on allografts infected with Pseudomonas in burned rats. Burns Incl. Therm. Inj. 13: 181, 1987.
15. Khanna, A. K., Cairns, V. R., Becker, C. G., and Hosenpud, J. D. TGF-β mimics and anti-TGb-β antibody abrogates the in vivo effects of cyclosporine. Transplantation 67: 882, 1999.
16. Derynck, R., Jarrett, J. A., Chen, E. Y., et al. Human TGF-β complementary DNA sequence and expression in normal and transformed cells. Nature 316: 701, 1985.
17. Derynck, R. Transforming growth factor beta. In A. W. Thomson (Ed.), The Cytokine Handbook. San Diego: Academic Press, 1994. Pp. 319-321.
18. 1: A multifunctional effector in both soft and hard tissue regeneration. Growth Factors Health Dis. 4: 89, 1990.
19. Wolf, G., Thaiss, F., and Stahl, R. A. K. Cyclosporine stimulates expression of TGF-β in renal cells: Possible mechanism of cyclosporine's antiproliferative effects. Transplantation 60: 237, 1995.
20. Platt, J. L. (Ed.). Hyperacute Xenograft Rejection. New York: Springer-Verlag, 1995. Pp. 56-70.
21. Braathen, L. R., and Thorsby, E. Studies on human epidermal Langerhans' cells: I. Allo-activating and antigen-presenting capacity. Scand. J Immunol. 11: 401, 1980.
22. Steinmuller, D., and Wachtel, S. S. Transplantation biology and immunogenetics of murine skin-specific (Sk) alloantigens. Transplant. Proc. 12 (3 Suppl. 1): 100, 1980.
23. Uchiyama, H., Kong, Y., Kishihara, K., Sugimachi, K., and Nomoto, K. Approach to withdrawal from tacrolimus in a fully allogeneic murine skin graft model. Immunology 97: 294, 1999.
24. 1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. U.S.A. 88: 2918, 1991.
25. 1 gene results in multifocal inflammatory disease. Nature 359: 693, 1992.
26. Akhurst, R. J., and Balmain, A. Genetic events and the role of TGF-β in epithelial tumour progression. J. Pathol. 187: 82, 1999.
27. 1. J. Exp. Med. 172: 1777, 1990.
28. Deng, S., Ketchum, R. J., Yang, Z. D., et al. IL-10 and TGF-β gene transfer to rodent islets: Effect on xenogeneic islet graft survival in naive and B-cell-deficient mice. Transplant. Proc. 29: 2207, 1997.
29. 1 improves wound healing and random flap survival in normal and irradiated rats. Arch. Otolaryngol. Head Neck Surg. 122: 171, 1996.
30. 1 in rats. Transplantation 58: 392, 1994.
31. Waltenberger, J., Miyazono, K., Funa, K., et al. TGF-β and organ transplantation. Transplant. Proc. 25: 2038, 1993.
32. Kehrl, J. H., Wakefield, L. M., Roberts, A. B., et al. Production of TGF-β by human T lymphocytes and its potential role in regulation of T cell growth. J. Exp. Med. 163: 1037, 1986.
33. Fontana, A., Hengartner, H., de Tribolet, N., and Weber, E. Glioblastoma cells release interleukin-1 and factors inhibiting interleukin-2-mediated effects. J. Immunol. 132: 1837, 1984.
34. Kehrl, J. H., Taylor, A. S., Delsing, G. A., Roberts, A. B., Sporn, M. B., and Fauci, A. S. Further studies of the role of TGF-β in human B cell function. J. Immunol. 143: 1868, 1989.
35. Kehrl, J. H., Thevenin, C., Reickmann, P., and Fauci, A. S. TGF-β suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J. Immunol. 146: 4016, 1991.
36. 1 modulates the expression of class II histocompatibility antigens on human cells. J. Immunol. 140: 4217, 1988.
37. Gill, R. G. TGF-β prevents islet allograft rejection. Transplant. Proc. 23: 747, 1991.
38. 1 in mice: Stimulation by cyclosporine. Transplantation 63: 1037, 1997.
39. 1 in humans: Stimulation by cyclosporine. Transplantation 65: 313, 1998.
40. Llull, R., Lee, T. P., Vu, A. N., Black, K. S., and Hewitt, C. W. Site-specific immune suppression with topical cyclosporine: Synergism with combined topical corticosteroid added during the maintenance phase. Transplantation 59: 1483, 1995.
41. Fujita, T., Takahashi, S., Yagihashi, A., et al. Prolonged survival of rat skin allograft by treatment with FK506 ointment. Transplantation 64: 922, 1997.
42. Shirbacheh, M. V., Harralson, T. A., Jones, J. W., et al. Pharmacokinetic advantage of intraarterial cyclosporin A delivery to vascularly isolated rabbit forelimb: II. Dose dependence. J. Pharmacol. Exp. Ther. 289: 1191, 1999.
43. Gruber, S. A., Cipolle, R. J., Canafax, D. M., et al. An implantable pump for intrarenal infusion of immunosuppressants in a canine autotransplant model. Pharm. Res. 5: 781, 1988.
44. 1. Ann. Surg. 220: 508, 1994.